All In Biotech

NDA 020849 · Baxter Hlthcare

Prosol 20% Sulfite Free In Plastic Container

Amino Acids · Injection · Amino Acid

Last checked: Nov 20, 2026Latest source record: Sep 23, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Aug 26, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30,323

6,603 Phase 3, 2,682 recruiting

FAERS reports

13

9 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 7, 2020.

PROSOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PROSOL may be used to treat negative nitrogen balance in patients. • PROSOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PROSOL may be used to treat negative nitrogen balance in patents. ( 1 )

Mechanism: PROSOL is used as a supplement of nutrition in patients, providing amino acids parenterally. The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source of energy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER · AMINO ACIDS 20% (20GM/100ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amino Acids" as an intervention, any sponsor and status, largest first.

All 30,323 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • sepsis3
  • back pain2
  • body temperature increased2
  • cardiac arrest2
  • death2
  • headache2
  • malaise2
  • nausea2
  • off label use2
  • vomiting2
  • agitation1
  • anaemia1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20141
20161
20171
20181
20195
20242
20261

Recalls

1 FDA enforcement reports for this application.

  • Aug 4, 2014 · Class II · Terminated

    Presence of Particulate Matter: identification of particulates in a retention sample that have been identified as a mixture of the amino acid leucine and inorganic material (containing iron, silicone and chlorine).

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL;...

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,551 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.